Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Vision for Digital Health Transformation


Foreword by the Minister of Health

In the following pages, we reveal a compelling vision for the future of digital health in Lebanon—an innovative blueprint developed through collaborative, forward-thinking, and inclusive efforts. With the recognition of digital technology as an integral driver of healthcare improvement, the Ministry of Public Health (MoPH) has been at the forefront, rallying essential stakeholders and orchestrating strategic discussions aimed at redefining our healthcare landscape.

This grand vision is grounded in the National Health Strategy, launched by the MoPH in January 2023. Recognizing the importance of digital health transformation, this strategy identified it as a crucial pillar. From this sturdy foundation, the Digital Health Retreat was organized on May 18, 2023. This retreat acted as a catalyst, creating an arena for stakeholders to identify the challenges and opportunities present in Lebanon's digital health ecosystem. A consensus was reached, emphasizing the pressing need for a consolidated vision that enables our healthcare system and augments health outcomes for our people.

Our healthcare sector, while resilient, faces its fair share of hurdles. With this understanding, and building upon the significant investments in digital health stipulated by the National Health Strategy, our vision aims to utilize digital solutions to overcome these barriers, thereby enriching healthcare outcomes. This is a vision of synergy, empowerment, and readiness for the evolving landscape of healthcare.

Our transformative vision transcends policy constraints. It establishes a detailed blueprint for developing a resilient digital health infrastructure. These strategies encompass a multitude of aspects—from digital platforms and mobile applications to health information exchange systems and more.
The implications of this digital health transformation are immense. From improved care coordination to enhanced population health outcomes, this vision for digital health, inherent in the National Health Strategy, is poised to serve as a guiding beacon for our future. Our journey begins here, and we invite you to join us as we map the pathway for a healthier Lebanon. Together, we can transform this vision into reality.

Vision for Digital Health Transformation
    1
    ...
ATC Name B/G Ingredients Dosage Form Price ↑
A02AC10 RENNIE B Magnesium carbonate - 80mg, Calcium carbonate - 680mg Tablet, chewable 200,233 L.L
A02BC01 RISEK G Omeprazole - 20mg 20mg Capsule, enteric coated 302,365 L.L
A02BC01 RISEK G Omeprazole - 40mg 40mg Capsule, enteric coated 522,755 L.L
A02BC01 RISEK G Omeprazole (sodium) - 40mg 40mg Injectable lyophilised powder for solution 592,635 L.L
A02BC02 RAZON 40 G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 727,019 L.L
A02BC02 RAZON 40 G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 1,252,461 L.L
A02BC02 RAZON 20 G Pantoprazole (sodium) - 20mg 20mg Tablet, enteric coated 747,176 L.L
A02BC04 RABEC G Rabeprazole (sodium) - 10mg 10mg Tablet, film coated 212,327 L.L
A02BC04 RAMEP G Rabeprazole (sodium) - 10mg 10mg Tablet, gastroresistant 795,310 L.L
A02BC04 RABEC G Rabeprazole (sodium) - 20mg 20mg Tablet, film coated 212,327 L.L
A02BC04 RABEZOL 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 282,847 L.L
A02BC04 RABEZOL 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 639,925 L.L
A02BC04 RAMEP G Rabeprazole (sodium) - 20mg 20mg Tablet, gastroresistant 499,046 L.L
A02BC04 RAZOLE 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 282,847 L.L
A02BC04 RAZOLE 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 639,925 L.L
A03CB01 RESTROPINAL PEDIATRIC B Butobarbital - 2mg/ml, Methyl hyoscine nitrate - 0.1mg/ml Drops 197,097 L.L
A06AX05 RESOLOR B Prucalopride succinate - 2mg 2mg Tablet, film coated 5,251,736 L.L
A06AX05 RESOLOR B Prucalopride succinate - 1mg 1mg Tablet, film coated 3,273,600 L.L
A07XA04 RACECADOTRIL ARROW G Racecadotril - 100mg 100mg Capsule 583,228 L.L
A07XA04 RACECADOTRIL BGR G Racecadotril - 100mg 100mg Capsule 575,165 L.L
A07XA04 RACECADOTRIL BIOGARAN CONSEIL G Racecadotril - 100mg 100mg Capsule 287,582 L.L
A10AD06 RYZODEG BioTech Insulin degludec - 70%, Insulin aspart - 30% 100IU/ml Injectable solution 7,058,661 L.L
A10BX02 REPAGLINIDE ARROW LAB G Repaglinide - 2mg 2mg Tablet 831,839 L.L
A10BX02 REPAGLINIDE ARROW LAB G Repaglinide - 0.5mg 0.5mg Tablet 831,839 L.L
A10BX02 REPAGLINIDE ARROW LAB G Repaglinide - 1mg 1mg Tablet 831,839 L.L
A11GA01 REDOXON EFF.ORANGE B Ascorbic acid (vit C) - 1g 1g Tablet, effervescent 366,869 L.L
B01AF01 RIBAVAN G Rivaroxaban - 2.5mg 2.5mg Tablet, film coated 3,199,625 L.L
B01AF01 RIBAVAN G Rivaroxaban - 15mg 15mg Tablet, film coated 1,343,843 L.L
B01AF01 RIXALTA 15 G Rivaroxaban - 15mg 15mg Tablet, film coated 1,164,664 L.L
B01AF01 RIBAVAN G Rivaroxaban - 20mg 20mg Tablet, film coated 1,343,843 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025